Organogenesis Slips After Arthritis-Treatment Trial Misses Primary Endpoint

Dow Jones09-27

By Kelly Cloonan

Shares of Organogenesis declined after the regenerative medicine company said a trial for an osteoarthritis treatment didn't achieve its primary endpoint.

The stock fell 11%, to $4.16, midday Friday. Shares are up 30% this year.

Organogenesis said Thursday that a second Phase 3 trial for ReNu didn't achieve a statistically significant difference in knee-pain reduction at six months compared with the control group.

ReNu did show improved baseline pain reduction compared with the first Phase 3 trial, though, the Canton, Mass., company said.

ReNu is a cryopreserved amniotic suspension allograft that aims to manage symptoms associated with knee osteoarthritis.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

September 26, 2025 14:09 ET (18:09 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2570836004?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-27 02:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2570836004","market":"sg","top_or_hot":-1,"title":"Organogenesis Slips After Arthritis-Treatment Trial Misses Primary Endpoint","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Organogenesis declined after the regenerative medicine company said a trial for an osteoarthritis treatment didn't achieve its primary endpoint. \n</p>\n<p>\n  The stock fell 11%, to $4.16, midday Friday. Shares are up 30% this year. \n</p>\n<p>\n  Organogenesis said Thursday that a second Phase 3 trial for ReNu didn't achieve a statistically significant difference in knee-pain reduction at six months compared with the control group. \n</p>\n<p>\n  ReNu did show improved baseline pain reduction compared with the first Phase 3 trial, though, the Canton, Mass., company said. \n</p>\n<p>\n  ReNu is a cryopreserved amniotic suspension allograft that aims to manage symptoms associated with knee osteoarthritis. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 26, 2025 14:09 ET (18:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Organogenesis Slips After Arthritis-Treatment Trial Misses Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrganogenesis Slips After Arthritis-Treatment Trial Misses Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-09-27 02:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Organogenesis declined after the regenerative medicine company said a trial for an osteoarthritis treatment didn't achieve its primary endpoint. \n</p>\n<p>\n  The stock fell 11%, to $4.16, midday Friday. Shares are up 30% this year. \n</p>\n<p>\n  Organogenesis said Thursday that a second Phase 3 trial for ReNu didn't achieve a statistically significant difference in knee-pain reduction at six months compared with the control group. \n</p>\n<p>\n  ReNu did show improved baseline pain reduction compared with the first Phase 3 trial, though, the Canton, Mass., company said. \n</p>\n<p>\n  ReNu is a cryopreserved amniotic suspension allograft that aims to manage symptoms associated with knee osteoarthritis. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 26, 2025 14:09 ET (18:09 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2570836004","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2570836004","pubTimestamp":1758910140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Organogenesis declined after the regenerative medicine company said a trial for an osteoarthritis treatment didn't achieve its primary endpoint.The stock fell 11%, to $4.16, midday Friday. Shares are up 30% this year.Organogenesis said Thursday that a second Phase 3 trial for ReNu didn't achieve a statistically significant difference in knee-pain reduction at six months compared with the control group.ReNu did show improved baseline pain reduction compared with the first Phase 3 trial, though, the Canton, Mass., company said.ReNu is a cryopreserved amniotic suspension allograft that aims to manage symptoms associated with knee osteoarthritis.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ORGO":"Organogenesis Holdings Inc"},"translate_title":"关节炎治疗试验未达到主要终点后器官发生下滑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ORGO":0.9},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  Shares of Organogenesis declined after the regenerative medicine company said a trial for an osteoarthritis treatment didn't achieve its primary endpoint. \n\n\n  The stock fell 11%, to $4.16, midday Friday. Shares are up 30% this year. \n\n\n  Organogenesis said Thursday that a second Phase 3 trial for ReNu didn't achieve a statistically significant difference in knee-pain reduction at six months compared with the control group. \n\n\n  ReNu did show improved baseline pain reduction compared with the first Phase 3 trial, though, the Canton, Mass., company said. \n\n\n  ReNu is a cryopreserved amniotic suspension allograft that aims to manage symptoms associated with knee osteoarthritis. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 26, 2025 14:09 ET (18:09 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2570836004","isCrawlerRequest":true}